Grow Pharma is the latest cannabis company to join Drug Science’s observational study, T21, to help patients access more affordable medicinal cannabis.
The UK biopharmaceutical company announced last week it would be joining T21 to allow patients to continue accessing cannabis-based medicines at a reduced cost.
Launched by the UK charity Drug Science in 2019, T21 aims to build a strong evidence base for the safety and efficacy of cannabis medicines, with the goal of ultimately increasing access to them on the NHS.
Patients enrolled on the registry are able to access discounted private prescriptions for cannabis products, provided by industry partners including Khiron Life Sciences Corp, Leva, JMCC Group Canopy Growth (under the Spectrum Therapeutical brand) and Ethypharm.
The registry now has over 3,500 patients enrolled and has published a number of findings from the data, including how cannabis medicines can support a better quality of life, sleep, mood, reduced pain, PTSD and anxiety.
In January, Drug Science announced a number of changes to the project as it continues collecting data into its fourth year, including that the prices of products would now be set by the producers.
Announcing the news in a press release, Drug Science said having Grow Pharma on board would ‘help secure the future of the project’, allowing patients to continue with their medications and scientists to collect important data on their effects.
“We’re very happy that Grow Pharma has joined T21 and that they, and our existing partners, are allowing UK patients to access discounted prescriptions,” said chief executive of Drug Science, David Badcock.
“We already know that these drugs can benefit a wide range of conditions – from childhood epilepsy to chronic pain and PTSD. And as our study grows stronger, the closer we will get to widening public access to these important, life-changing medications.”
The addition of Grow Pharma as a partner allows T21 to extend its formulary, adding more cannabis-based medicines and offering more choice to patients taking part in the study.
Pierre van Weperen, chief executive of Grow Pharma, commented: “We are proud to be joining T21. Our involvement is testament to our mission of making quality cannabis medicines affordable for UK patients.
“We have been considering joining for some time and with some of the changes that have been made we feel the time is right. We look forward to working with Drug Science and with the clinics and producers involved in the study.”
The post Grow Pharma joins T21 to help patients access more affordable medicinal cannabis appeared first on Cannabis Health News.
